115309-58-5

Usage

Uses

Used in Pharmaceutical Research and Development:
6-Chloro-N-tert-butylnicotinamide is utilized as a key component in the discovery and synthesis of new drugs, leveraging its unique structural features and potential biological activities for the treatment of various medical conditions.
Used in Drug Design and Medicinal Chemistry:
In the field of drug design, 6-Chloro-N-tert-butylnicotinamide serves as a valuable building block for the creation of novel therapeutic agents. Its chemical properties allow for the exploration of its interactions with biological targets, potentially leading to the development of effective treatments for a variety of diseases.
Used in Biological Activity Studies:
6-Chloro-N-tert-butylnicotinamide is employed in biological assays and screenings to evaluate its potential as a therapeutic agent. Its specific properties may contribute to its efficacy in treating certain conditions, making it a subject of interest for further research in the pharmaceutical industry.

InChI:InChI=1/C10H13ClN2O/c1-10(2,3)13-9(14)7-4-5-8(11)12-6-7/h4-6H,1-3H3,(H,13,14)

Upstream product

• 58757-38-3 6-Chloronicotinoyl chloride 
• 75-64-9 tert-butylamine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 

Downstream Products

• 342417-04-3 N-tert-butyl-6-chloro-4-(o-tolyl)nicotinamide 
• 342417-05-4 N-tert-butyl-6-(morpholin-4-yl)-4-(o-tolyl)nicotinamide 
• 290297-36-8 N-methyl-N-[6-(morpholin-4-yl)-4-(o-tolyl)pyridin-3-yl]amine 
• 342417-07-6 [6-(morpholin-4-yl)-4-(o-tolyl)pyridin-3-yl]carbamic acid methyl ester 
• 290297-26-6 netupitant 
• 290297-25-5 methyl-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-amine 
• 342417-02-1 [6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl]carbamic acid methyl ester 
• 290296-68-3 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide 
• 1021464-00-5 6-chloro-N-(tert-butyl)-4-[(hydroxy)(4-chlorophenyl)methyl]pyridine-3-carboxamide 
• 881743-64-2 N-tert-butyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)nicotinamide 
• 342417-01-0 4-(2-methylphenyl)-6-(4-methylpiperazinyl)-3-pyridinecarboxamide 
• 342417-06-5 4-(2-methylphenyl)-6-(4-morpholinyl)-3-pyridinecarboxamide 
• 733805-18-0 N-tert-butyl-6-chloro-4-(4-fluoro-2-methylphenyl)nicotinamide 

Relevant academic research and scientific papers

NK1 receptor-targeting antagonist and application of same to chemotherapy-induced nausea and vomiting

The invention relates to a NK1 receptor-targeting antagonist and application of the same to chemotherapy-induced nausea and vomiting, belonging to the technical field of adjuvant therapeutics for tumor chemotherapy. The invention provides a compound as shown in a formula I which is described in the specification, or a racemate, stereoisomer, tautomer, isotopic label, oxynitride or pharmaceutically-acceptable salt thereof. The invention also provides a preparation method for the compound, a pharmaceutical compositions and the application of the compound or the racemate, stereoisomer, tautomer,isotopic label, oxynitride or pharmaceutically-acceptable salt thereof.

Deprotonation of pyridine carboxamides using lithium magnesiates bases

Regioselective deprotonation of N-methyl- and tert-butylpyridine carboxamides using lithium magnesiates bases was achieved at room temperature avoiding nucleophilic addition on the pyridine molecule and auto-condensation of the arylmetal intermediates on

Efficient synthesis of novel NK1 receptor antagonists: Selective 1,4-addition of Grignard reagents to 6-chloronicotinic acid derivatives

A new efficient synthesis of two novel classes of NK1 receptor antagonists, among them befetupitant and netupitant, starting from 6-chloronicotinic acid is described. The introduction of the o-tolyl substituent at C(4) of the pyridine ring was achieved by a one-pot selective 1,4-Grignard addition/oxidation sequence to 6-chloronicotinic acid or a derivative of it. The scope of this addition/oxidation sequence was examined. It was also shown that the carboxylic function can be converted to a methyl amino group by a Hofmann rearrangement followed by reduction. Furthermore, a new high-yielding synthesis of 2-(3,5-bistrifluoromethylphenyl)-2-methyl propionic acid based on the carbonylation of the tertiary alcohol obtained by Grignard addition of 3,5-bis(trifluoromethyl)bromobenzene to acetone was established.

Research and development of an efficient process for the construction of the 2,4,5-substituted pyridines of NK-1 receptor antagonists

Roche has identified a 2,4,5-trisubstituted pyridine template for a new class of potent NK1 receptor antagonists. Previous strategies for construction of the pyridine core of these NK-1 receptor antagonists involved functionalization of a 2,5-disubstituted pyridine. We now report on construction of the pyridine core from commodity components. Shestopalov reported the synthesis of trans-4′-aryl-5′-cyano-1′,2′,3′, 4′-tetrahydro-6′-hydroxy-2′-oxo-1,3′-bipyridinium inner salts from 1-(2-amino-2-oxo-ethyl)pyridinium chloride, aromatic aldehydes, and ethyl cyanoacetate in the presence of a base. Reaction of these salts with phosphorus oxychloride affords 4-aryl-3-cyano-2,6-dichloropyridines. These are efficiently converted to nicotinamide precursors of the Roche NK-1 receptor antagonists by regioselective displacement of one chlorine by an amine, hydrogenolysis of the remaining chlorine, and nitrile hydrolysis.

NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-4(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE

The present invention relates to a new crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide characterized by the following X-ray

Amide derivative

A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2; R1is hydogen atom, optionally substituted alkyl, etc.; R2and R3are independently optionally substituted alkyl, etc.; R4and R5are independently hydrogen atom or optionally substituted alkyl; R6is hydrogen atom, hydroxy or alkyl; or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.

Process for the preparation of pyridine derivatives

A process is described for preparing certain 4-alkyl- or 4-aryl-pyridine derivatives.

4-phenyl-pyridine derivatives

The compounds of the related invention are related to 4-phenyl-pyridine derivatives connected by a bridge containing oxygen or nitrogen to a phenyl derivative.